Phase 2 Endometrial Cancer Trial, Recruiting NCT04683653 Sponsor: University of Chicago Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 2 Endometrial Cancer Trial, Recruiting

NCT04683653
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with primary cervical cancer or uterine cancer of any type
  • People who are 18 years of age or older
  • People whose cancer has not spread to distant parts of the body, based on international gynaecological cancer staging guidelines
  • People who have already had surgery (such as a hysterectomy) with the goal of fully removing the cancer, with no visible cancer remaining after the operation
  • People whose treatment team has recommended pelvic radiation therapy on its own, without chemotherapy given at the same time (chemotherapy given before or after radiation is acceptable)
  • People who are reasonably physically functional in daily life (confirm with trial site for the specific fitness level required)
  • People who are willing and able to give informed consent to participate

Who may not be able to join:

  • People whose cancer has spread to distant parts of the body, based on clinical assessment or imaging
  • People who are receiving chemotherapy at the same time as the study treatment
  • People who have visible cancer remaining after surgery, or cancer detected on imaging or during the operation itself
  • People who have a history of small bowel blockage, inflammatory bowel disease, irritable bowel syndrome, a connective tissue disorder requiring ongoing treatment, or previous radiation therapy to the pelvis
  • People who have unresolved moderate or severe diarrhoea or abdominal/pelvic pain related to chemotherapy that requires medication, before radiation begins
  • People whose treatment team has recommended radiation to the lymph nodes near the aorta (the large artery in the abdomen)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Christina Son, MD, University of Chicago

Phone: 773-702-6870

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
15 January 2021
Est. completion
22 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

The Maximum Tolerated Dose of Hypofractionated Whole Pelvic Radiation Treatment (Phase 1); Change in patient-reported acute gastrointestinal side effects after completion of hypofractionated radiation (Phase 2)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov